These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 35886976)

  • 1. Targeting the Microenvironment for Treating Multiple Myeloma.
    Neumeister P; Schulz E; Pansy K; Szmyra M; Deutsch AJ
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The yin-yang effects of immunity: From monoclonal gammopathy of undetermined significance to multiple myeloma.
    Yi Z; Ma T; Liu J; Tie W; Li Y; Bai J; Li L; Zhang L
    Front Immunol; 2022; 13():925266. PubMed ID: 35958625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple Myeloma and the Immune Microenvironment.
    Kawano Y; Roccaro AM; Ghobrial IM; Azzi J
    Curr Cancer Drug Targets; 2017; 17(9):806-818. PubMed ID: 28201978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma.
    Manier S; Kawano Y; Bianchi G; Roccaro AM; Ghobrial IM
    Curr Opin Hematol; 2016 Jul; 23(4):426-33. PubMed ID: 27101529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches.
    Lagreca I; Riva G; Nasillo V; Barozzi P; Castelli I; Basso S; Bettelli F; Giusti D; Cuoghi A; Bresciani P; Messerotti A; Gilioli A; Pioli V; Colasante C; Vallerini D; Paolini A; Maccaferri M; Donatelli F; Forghieri F; Morselli M; Colaci E; Leonardi G; Marasca R; Potenza L; Manfredini R; Tagliafico E; Trenti T; Comoli P; Luppi M
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; Rajkumar SV
    Curr Hematol Malig Rep; 2010 Apr; 5(2):62-9. PubMed ID: 20425398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Smoldering multiple myeloma].
    Fouquet G; Guidez S; Herbaux C; Demarquette H; Leleu X
    Rev Med Interne; 2014 Apr; 35(4):243-9. PubMed ID: 24050785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
    Ho M; Patel A; Goh CY; Moscvin M; Zhang L; Bianchi G
    Leukemia; 2020 Dec; 34(12):3111-3125. PubMed ID: 33046818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease.
    Isola I; Brasó-Maristany F; Moreno DF; Mena MP; Oliver-Calders A; Paré L; Rodríguez-Lobato LG; Martin-Antonio B; Cibeira MT; Bladé J; Rosiñol L; Prat A; Lozano E; Fernández de Larrea C
    Front Immunol; 2021; 12():792609. PubMed ID: 34880879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pathogenesis of multiple myeloma].
    Rasche L; Weinhold N
    Internist (Berl); 2019 Jan; 60(1):3-9. PubMed ID: 30536029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deep Learning Enables Spatial Mapping of the Mosaic Microenvironment of Myeloma Bone Marrow Trephine Biopsies.
    Hagos YB; Lecat CSY; Patel D; Mikolajczak A; Castillo SP; Lyon EJ; Foster K; Tran TA; Lee LSH; Rodriguez-Justo M; Yong KL; Yuan Y
    Cancer Res; 2024 Feb; 84(3):493-508. PubMed ID: 37963212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
    Hillengass J; Moehler T; Hundemer M
    Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Dimensional Immune Profiling of Smoldering Multiple Myeloma Distinguishes Distinct Tumor Microenvironments.
    Fernandez N; Perumal D; Rahman A; Kim-Schulze S; Yesil J; Auclair D; Adams H; Parekh S; Gnjatic S; Cho HJ
    Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):853-862. PubMed ID: 35945129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
    Giannakoulas N; Ntanasis-Stathopoulos I; Terpos E
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.
    Noll JE; Williams SA; Tong CM; Wang H; Quach JM; Purton LE; Pilkington K; To LB; Evdokiou A; Gronthos S; Zannettino AC
    Haematologica; 2014 Jan; 99(1):163-71. PubMed ID: 23935020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients.
    Costa F; Vescovini R; Marchica V; Storti P; Notarfranchi L; Dalla Palma B; Toscani D; Burroughs-Garcia J; Catarozzo MT; Sammarelli G; Giuliani N
    Front Immunol; 2020; 11():613007. PubMed ID: 33488620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells.
    van Nieuwenhuijzen N; Spaan I; Raymakers R; Peperzak V
    Cancer Res; 2018 May; 78(10):2449-2456. PubMed ID: 29703720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The progress in multiple myeloma.
    Hatjiharissi P
    Hell J Nucl Med; 2023; 26 Suppl():30-35. PubMed ID: 37658559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.